Prognostic significance of pan-immune-inflammation value in hepatocellular carcinoma treated by curative radiofrequency ablation: potential role for individualized adjuvant systemic treatment

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation . Cell. 2011;144(5):646–674. doi: 10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, Mcmillan DC, et al. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493-503–e503. doi: 10.1016/S1470-2045(14)70263-3.
   PubMed Web of Science ®Google Scholar
• Kubes P, Jenne C. Immune responses in the liver . Annu Rev Immunol. 2018;36(1):247–277. doi: 10.1146/annurev-immunol-051116-052415.
   PubMed Web of Science ®Google Scholar
• Zheng J, Seier K, Gonen M, et al. Utility of serum inflammatory markers for predicting microvascular invasion and survival for patients with hepatocellular carcinoma . Ann Surg Oncol. 2017;24(12):3706–3714. doi: 10.1245/s10434-017-6060-7.
   PubMed Web of Science ®Google Scholar
• Cabillic F, Corlu A. Regulation of transdifferentiation and retrodifferentiation by inflammatory cytokines in hepatocellular carcinoma. Gastroenterology. 2016;151(4):607–615. doi: 10.1053/j.gastro.2016.06.052.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang Y, Zhang XY, et al. Nomogram based on neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio to predict recurrence in patients with hepatocellular carcinoma after radiofrequency ablation. Cardiovasc Intervent Radiol. 2021;44(10):1551–1560. doi: 10.1007/s00270-021-02872-8.
   PubMed Web of Science ®Google Scholar
• Canale M, Ulivi P, Foschi FG, et al. Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma . Crit Rev Oncol Hematol. 2018;129:44–53.
   PubMed Web of Science ®Google Scholar
• Chu MO, Shen CH, Chang TS, et al. Pretreatment inflammation-based markers predict survival outcomes in patients with early stage hepatocellular carcinoma after radiofrequency ablation . Sci Rep. 2018;8(1):16611. doi: 10.1038/s41598-018-34543-z.
   PubMed Web of Science ®Google Scholar
• Shen Y, Wang H, Li W, et al. Prognostic significance of the CRP/alb and neutrophil to lymphocyte ratios in hepatocellular carcinoma patients undergoing TACE and RFA. J Clin Lab Anal. 2019;33(9):e22999.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Abe K, Fujita M, et al. Combination of psoas muscle mass index and neutrophil-to-lymphocyte ratio as a noninvasive prognostic marker in hepatocellular carcinoma patients undergoing radiofrequency ablation . Eur J Gastroenterol Hepatol. 2023;35(5):568–574. doi: 10.1097/MEG.0000000000002532.
   PubMed Web of Science ®Google Scholar
• Xin Y, Zhang X, Li Y, et al. A systemic inflammation response index (SIRI)-based nomogram for predicting the recurrence of early stage hepatocellular carcinoma after radiofrequency ablation . Cardiovasc Intervent Radiol. 2022;45(1):43–53. doi: 10.1007/s00270-021-02965-4.
   PubMed Web of Science ®Google Scholar
• Pan J, Chen S, Tian G, et al. Preoperative albumin-bilirubin grade with prognostic nutritional index predicts the outcome of patients with early-stage hepatocellular carcinoma after percutaneous radiofrequency ablation . Front Med . 2020;7:584871. doi: 10.3389/fmed.2020.584871.
   Web of Science ®Google Scholar
• Yang Q, Yu XL, Wang Y, et al. Predictive effects of a combined indicator in patients with hepatocellular carcinoma after thermal ablation . J Cancer Res Ther. 2020;16(5):1038–1050. doi: 10.4103/jcrt.JCRT_1080_19.
   PubMed Web of Science ®Google Scholar
• Xin Y, Yang Y, Liu N, et al. Prognostic significance of systemic immune-inflammation index-based nomogram for early stage hepatocellular carcinoma after radiofrequency ablation. J Gastrointest Oncol. 2021;12(2):735–750. doi: 10.21037/jgo-20-342.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liang Y, Zhong D, et al. Prognostic value of inflammation-immunity-nutrition score in patients with hepatocellular carcinoma treated with anti-PD-1 therapy . J Clin Lab Anal. 2022;36(5):e24336. doi: 10.1002/jcla.24336.
   PubMed Web of Science ®Google Scholar
• Xie H, Ruan G, Wei L, et al. Comprehensive comparative analysis of prognostic value of serum systemic inflammation biomarkers for colorectal cancer: results from a large multicenter collaboration [J]. Front Immunol. 2022;13:1092498. doi: 10.3389/fimmu.2022.1092498.
   PubMed Web of Science ®Google Scholar
• Fucà G, Guarini V, Antoniotti C, et al. The pan-immune-inflammation value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the valentino and TRIBE first-line trials. Br J Cancer. 2020;123(3):403–409. doi: 10.1038/s41416-020-0894-7.
   PubMed Web of Science ®Google Scholar
• Hack SP, Spahn J, Chen M, et al. IMbrave 050: a phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol. 2020;16(15):975–989. doi: 10.2217/fon-2020-0162.
   PubMed Web of Science ®Google Scholar
• Huang J, Yan L, Cheng Z, et al. A randomized trial comparing ­radiofrequency ablation and surgical resection for HCC conforming to the milan criteria . Ann Surg. 2010;252(6):903–912. doi: 10.1097/SLA.0b013e3181efc656.
   PubMed Web of Science ®Google Scholar
• EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. ELECTRONIC ADDRESS E E E, EUROPEAN ASSOCIATION FOR THE STUDY OF THE L. EASL clinical practice guidelines: management of hepatocellular carcinoma . J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma . Nat Rev Clin Oncol. 2022;19(3):151–172. doi: 10.1038/s41571-021-00573-2.
   PubMed Web of Science ®Google Scholar
• EUROPEAN ASSOCIATION FOR STUDY OF L, EUROPEAN ORGANISATION FOR R, TREATMENT OF C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma . Eur J Cancer. 2012;48(5):599–641.
   PubMed Web of Science ®Google Scholar
• Jaillon S, Ponzetta A, DI Mitri D, et al. Neutrophil diversity and plasticity in tumour progression and therapy . Nat Rev Cancer. 2020;20(9):485–503. doi: 10.1038/s41568-020-0281-y.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang Y, Ding Y, et al. Platelet-mediated tumor metastasis mechanism and the role of cell adhesion molecules . Crit Rev Oncol Hematol. 2021;167:103502. doi: 10.1016/j.critrevonc.2021.103502.
   PubMedGoogle Scholar
• Olingy CE, Dinh HQ, Hedrick CC. Monocyte heterogeneity and functions in cancer . J Leukoc Biol. 2019;106(2):309–322. doi: 10.1002/JLB.4RI0818-311R.
   PubMed Web of Science ®Google Scholar
• Corti F, Lonardi S, Intini R, et al. The pan-immune-inflammation value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors . Eur J Cancer. 2021;150:155–167.
   PubMed Web of Science ®Google Scholar
• Şahin AB, Cubukcu E, Ocak B, et al. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy. Sci Rep. 2021;11(1):14662. doi: 10.1038/s41598-021-94184-7.
   PubMed Web of Science ®Google Scholar
• Kucuk A, Topkan E, Ozkan EE, et al. A high pan-immune-inflammation value before chemoradiotherapy indicates poor outcomes in patients with small-cell lung cancer. Int J Immunopathol Pharmacol. 2023;37:3946320231187759. doi: 10.1177/03946320231187759.
   Web of Science ®Google Scholar
• Yekedüz E, Tural D, Ertürk İ, et al. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study. J Cancer Res Clin Oncol. 2022;148(12):3537–3546. doi: 10.1007/s00432-022-04055-5.
   PubMed Web of Science ®Google Scholar
• Fucà G, Beninato T, Bini M, et al. The pan-immune-inflammation value in patients with metastatic melanoma receiving first-line therapy. [Target Oncol. 2021;16(4):529–536. J doi: 10.1007/s11523-021-00819-0.
   PubMed Web of Science ®Google Scholar
• Chen Y, Gong L, Gu P, et al. Pan-immune-inflammation and its ­dynamics: predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy . BMC Cancer. 2023;23(1):944. doi: 10.1186/s12885-023-11366-4.
   PubMed Web of Science ®Google Scholar
• Wang K, Wang C, Jiang H, et al. Combination of ablation and immunotherapy for hepatocellular carcinoma: where we are and where to go . Front Immunol. 2021;12:792781. doi: 10.3389/fimmu.2021.792781.
   PubMed Web of Science ®Google Scholar
• Liang X, Liu Q, Zhu S, et al. GSDME has prognostic and immunotherapeutic significance in residual hepatocellular carcinoma after insufficient radiofrequency ablation. J Transl Oncol. 2023;39:101796. doi: 10.1016/j.tranon.2023.101796.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Wang X, Li R, et al. Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within milan criteria: a multicenter analysis. J Gastroenterol. 2022;57(9):684–694. doi: 10.1007/s00535-022-01895-3.
   PubMed Web of Science ®Google Scholar
• Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for ­hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial . Lancet Oncol. 2015;16(13):1344–1354. doi: 10.1016/S1470-2045(15)00198-9.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi: 10.1056/NEJMoa1915745.
   PubMed Web of Science ®Google Scholar